Members are advised of an Amendment to the Australian Rules of Racing, effective 1 November 2016.
AR.177B(2) is the list of specified substances and categories of substances for the purposes of the out-of-competition testing rule AR.177B.
The list must be periodically updated to include new substances and classes of substances that are identified by Racing Australia as risks to the integrity of racing and to the welfare of horses.
The updated AR.177B(2) appears below with 3 additional classes of substances and a change in order to a more logical progression. Racing Australia is of the view that these 3 substances have no place in the treatment of racehorses and that their use is a risk to the integrity of racing and the welfare of horses.
The three new categories of substance in the re-ordered list in AR.177B(2) are:
(i) (g) haematopoietic growth factors, including but not limited to filgrastim.
(ii) (l) corticotrophins, including adrenocorticotropic hormone (ACTH) and tetracosactrin (tetracosactide), and corticotrophin releasing factors.
(iii) (w) zoledronic acid and any other bisphosphonate drug not registered for veterinary use in Australia.
1. Delete AR.177B(2) and replace with the following:
“(2) For the purposes of subrule (1), the following substances are specified as prohibited substances:-
(a) erythropoiesis-stimulating agents, including but not limited to erythropoietin (EPO), epoetin alfa, epoetin beta, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta (Mircera),
(b) non-erythropoietic EPO-receptor agonists,
(c) hypoxia-inducible factor (HIF) stabilisers, including but not limited to cobalt and FG-4592,
(d) HIF activators, including but not limited to argon and xenon,
(e) allosteric effectors of haemoglobin, including but not limited to ITPP (myo-inositol trispyrophosphate),
(f) oxygen carriers including but not limited to perfluorochemicals, efaproxiral and modified haemoglobin products,
(g) haematopoietic growth factors, including but not limited to filgrastim,
(i) growth hormones and their releasing factors,
(j) insulin-like growth factor-1,
(k) ynthetic proteins and peptides and synthetic analogues of endogenous proteins and peptides not registered for medical or veterinary use in Australia,
(l) corticotrophins, including adrenocorticotrophic hormone (ACTH) and tetracosactrin (tetracosactide), and corticotrophin releasing factors,
(m) anabolic androgenic steroids (other than an anabolic androgenic steroid which is present at or below the relevant concentrations set out in AR.178C(1)),
(n) selective androgen receptor modulators (SARMS),
(o) selective estrogen receptor modulators (SERMS),
(p) selective opioid receptor modulators (SORMS),
(q) peroxisome proliferator activated receptor δ (PPARδ) agonists, including but not limited to GW 1516,
(r) AMPK activators, including but not limited to AICAR (5-amino-1- β-D-ribofuranosyl-imidazole-4-carboxamide),
(s) other agents that directly or indirectly affect or manipulate gene expression,
(t) agents modifying myostatin function, including but not limited to myostatin inhibitors,
(u) thymosin beta,
(v) venoms of any species or derivatives thereof,
(w) zoledronic acid and any other bisphosphonate drugs not registered for veterinary use in Australia
(x) substances listed in Schedule 8 and Schedule 9 of the Standard for the Uniform Scheduling of Medicines and Poisons contained in the Australian Poisons Standard,
(y) metabolites, artifacts and isomers of any of the substances specified in paragraphs (a) to (x).”
Date of Effect: 1 November, 2016